Intriguingly, we find that CCL-18 and VEGF synergistically promote breast cancer migration and invasion, and this response is diminished via treatment of cells with the Rho-associated kinase (ROCK) inhibitor(s) Y-27632 or GSK429286A, delineating a unique targetable regulatory role for the Rho-GTPases. Here, CCL18 is linked to breast cancer.